Radiopharm Theranostics Files 6-K
Ticker: RDPTF · Form: 6-K · Filed: Jan 21, 2025 · CIK: 1949257
| Field | Detail |
|---|---|
| Company | Radiopharm Theranostics Ltd (RDPTF) |
| Form Type | 6-K |
| Filed Date | Jan 21, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, foreign-private-issuer, disclosure
TL;DR
Radiopharm Theranostics files routine 6-K, confirms 20-F annual report filing.
AI Summary
Radiopharm Theranostics Limited filed a Form 6-K on January 21, 2025, reporting information as a foreign private issuer. The filing indicates the company will file annual reports under Form 20-F and is not furnishing information under Rule 12g3-2(b). The company's principal executive office is located in Carlton South, Victoria, Australia.
Why It Matters
This filing provides routine disclosure for Radiopharm Theranostics as a foreign private issuer, informing investors about its reporting status with the SEC.
Risk Assessment
Risk Level: low — This is a standard procedural filing for a foreign private issuer and does not contain new material financial or operational information.
Key Players & Entities
- Radiopharm Theranostics Limited (company) — Registrant
- 001-41621 (company) — SEC File Number
- 20250121 (date) — Filing Date
- Form 6-K (document) — Filing Type
- Form 20-F (document) — Annual Report Form
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K is a Report of Foreign Private Issuer filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the month of January 2025.
Which annual report form does Radiopharm Theranostics Limited file?
Radiopharm Theranostics Limited files its annual reports under cover of Form 20-F.
Is Radiopharm Theranostics furnishing information under Rule 12g3-2(b)?
No, the company has indicated it is not furnishing information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
What is the principal executive office address of Radiopharm Theranostics Limited?
The principal executive office is located at Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia.
What is the SEC file number for Radiopharm Theranostics Limited?
The SEC file number for Radiopharm Theranostics Limited is 001-41621.
Filing Stats: 318 words · 1 min read · ~1 pages · Grade level 19.2 · Accepted 2025-01-21 08:00:21
Filing Documents
- ea0228146-6k_radio.htm (6-K) — 13KB
- ea022814601ex99-1_radio.htm (EX-99.1) — 40KB
- ex99-1_001.jpg (GRAPHIC) — 2KB
- 0001213900-25-004764.txt ( ) — 56KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2025 Commission File Number: 001-41621 RADIOPHARM THERANOSTICS LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes No If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- RADIOPHARM THERANOSTICS LIMITED EXPLANATORY NOTE Radiopharm Theranostics Limited (the “Company”) published one announcement (the “Public Notice”) to the Australian Securities Exchange on January 21, 2025 titled: - “Application for quotation of securities - RAD” A copy of the Public Notice is attached as an exhibit to this report on Form 6-K. This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. 1 EXHIBITS Exhibit Number Description 99.1 Application for quotation of securities - RAD 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. RADIOPHARM THERANOSTICS LIMITED Date: January 21, 2025 By: /s/ Phillip Hains Phillip Hains Company Secretary 3